Differential expression of $\alpha V\beta 3$ and $\alpha V\beta 6$ integrins in prostate cancer progression

Fabio Quaglia  
*Thomas Jefferson University*

Shiv Ram Krishn  
*Thomas Jefferson University*

Yanqing Wang  
*Roswell Park Comprehensive Cancer Center*

David W Goodrich  
*Roswell Park Comprehensive Cancer Center*

Peter McCue  
*Thomas Jefferson University*

Follow this and additional works at: [https://jdc.jefferson.edu/cbfp](https://jdc.jefferson.edu/cbfp)

Let us know how access to this document benefits you

See next page for additional authors

**Recommended Citation**

Quaglia, Fabio; Krishn, Shiv Ram; Wang, Yanqing; Goodrich, David W; McCue, Peter; Kossenkov, Andrew; Mandigo, Amy C; Knudsen, Karen; Weinreb, Paul H; Corey, Eva; Kelly, William Kevin; and Languino, Lucia R, 'Differential expression of $\alpha V\beta 3$ and $\alpha V\beta 6$ integrins in prostate cancer progression' (2021). *Department of Cancer Biology Faculty Papers*. Paper 176.

https://jdc.jefferson.edu/cbfp/176

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Cancer Biology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Differential expression of αVβ3 and αVβ6 integrins in prostate cancer progression

Fabio Quaglia1,2, Shiv Ram Krishn1,2, Yanqing Wang3, David W. Goodrich3, Peter McCue4, Andrew V. Kossenkov5, Amy C. Mandigo2, Karen E. Knudsen2, Paul H. Weinreb6, Eva Corey7, William K. Kelly6, Lucia R. Languino1,2*

1 Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, United States of America, 2 Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, United States of America, 3 Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States of America, 4 Department of Pathology, Thomas Jefferson University, Philadelphia, PA, United States of America, 5 Center for Systems and Computational Biology, Wistar Institute, Philadelphia, PA, United States of America, 6 Biogen Inc., Cambridge, MA, United States of America, 7 Department of Urology, University of Washington, Seattle, Washington, United States of America, 8 Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, United States of America

* lucia.languino@jefferson.edu

Abstract

Neuroendocrine prostate cancer (NEPrCa) arises de novo or after accumulation of genomic alterations in pre-existing adenocarcinoma tumors in response to androgen deprivation therapies. We have provided evidence that small extracellular vesicles released by PrCa cells and containing the αvβ3 integrin promote neuroendocrine differentiation of PrCa in vivo and in vitro. Here, we examined αvβ3 integrin expression in three murine models carrying a deletion of PTEN (SKO), PTEN and RB1 (DKO), or PTEN, RB1 and TRP53 (TKO) genes in the prostatic epithelium; of these three models, the DKO and TKO tumors develop NEPrCa with a gene signature comparable to those of human NEPrCa. Immunostaining analysis of SKO, DKO and TKO tumors shows that αvβ3 integrin expression is increased in DKO and TKO primary tumors and metastatic lesions, but absent in SKO primary tumors. On the other hand, SKO tumors show higher levels of a different αv integrin, αvβ6, as compared to DKO and TKO tumors. These results are confirmed by RNA-sequencing analysis. Moreover, TRAMP mice, which carry NEPrCa and adenocarcinoma of the prostate, also have increased levels of αvβ3 in their NEPrCa primary tumors. In contrast, the αvβ6 integrin is only detectable in the adenocarcinoma areas. Finally, analysis of 42 LuCaP patient-derived xenografts and primary adenocarcinoma samples shows a positive correlation between αvβ3, but not αvβ6, and the neuronal marker synaptophysin; it also demonstrates that αvβ3 is absent in prostatic adenocarcinomas. In summary, we demonstrate that αvβ3 integrin is upregulated in NEPrCa primary and metastatic lesions; in contrast, the αvβ6 integrin is confined to adenocarcinoma of the prostate. Our findings suggest that the αvβ3 integrin, but not αvβ6, may promote a shift in lineage plasticity towards a NE phenotype and might serve as an informative biomarker for the early detection of NE differentiation in prostate cancer.
program grant with the Pennsylvania Department of Health (H.R.T.) awarded to LRL (SAP 4100075266). The Department specifically disclaims responsibility for any analyses, interpretations, or conclusions. The establishment and characterization of the LuCaP PDXs was supported by the Pacific Northwest Prostate Cancer SPORE in the form of a grant awarded to EC (P50CA97186), the Department of Defense Prostate Cancer Biorepository Network in the form of a grant awarded to EC (WB1XWH-14-2-0183), and National Cancer Institute (NCI) in the form of a grant awarded to EC (P01 CA163227). The research reported in this publication utilized the shared flow cytometry, histopathology, and bioimaging facilities at the Sidney Kimmel Cancer Center (Thomas Jefferson University, Philadelphia, PA) that are supported by the National Cancer Institute of the National Institutes of Health in the form of a grant awarded to KEK (P30CA056036). NIH grants partially support the salaries of FQ, SRK, YW, DWG, AM, KEK, EC, LRL. Biogen Inc. provided support in the form of a salary for PW. The specific roles of this author are articulated in the ‘author contributions’ section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors of this study have read the journal’s policy and have the following competing interests: PW is an employee and a shareholder of Biogen Inc. Biogen holds patents covering avb6 antibodies and their uses for therapeutic purposes. However, this paper does not deal with the use of these antibodies for therapeutic purposes; these antibodies have been used just for immunoblotting in Fig S. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Introduction

Integrins are transmembrane adhesion receptors that are deregulated during cancer progression [1, 2]. Among others, αVβ6, αVβ3, α6β1, and α6β4 integrins are overexpressed in prostate cancer (PrCa) [3–6]; our group recently demonstrated that small extracellular vesicles released from PrCa cells and containing the αVβ3 integrin induce neuroendocrine differentiation (NED) in vitro and in vivo [7]. In contrast, the α5 and α7 integrin subunits have been reported to be downregulated in PrCa [8].

The αVβ3 integrin, also known as the vitronectin receptor, is composed of two subunits, αV and β3. It can bind a wide range of extracellular matrix components through its RGD motif (Arg-Gly-Asp) [9] and promotes invasion and adhesion of cancer cells to extracellular matrix proteins [2, 10, 11]. This RGD-integrin binding is also known to facilitate cell adhesion, virus entry, and infection by many human viruses [12], including metapneumovirus [13] and coxsackievirus [14]. According to a recent study, the interaction between the RGD motif in the spike protein of the SARS-Cov-2 virus (responsible for COVID-19) and integrins may promote the entry of the virus into the host cells [15]. The αVβ3 integrin itself is involved in a variety of processes, including angiogenesis and tumor metastasis [16]. While present at very low levels in normal prostate tissues, it is highly expressed in PrCa cells and in metastasis [7, 10, 17]. Given its widespread distribution in PrCa, αVβ3 has been explored as a therapeutic target in some studies [18, 19].

Disregulated expression of the αVβ6 integrin, another RGD binding integrin, has been associated with poor outcomes in different types of cancer [20]. Previous studies from our group showed that αVβ6 integrin is upregulated in PrCa and PrCa bone metastases [21, 22].

Neuroendocrine PrCa (NEPrCa), a subtype of PrCa that typically develops from subsets of castrate-resistant PrCa (CRPrCa) cells, is highly aggressive and usually metastasizes [23]. NEPrCa tumors may develop de novo or through the acquisition of alterations in pre-existing epithelial tumors in response to therapies as outlined in the recent National Cancer Institute workshop “Perspective on Lineage Plasticity and AR-independent PrCa” [24]. De novo NEPrCa appears to result from lineage reprogramming of mature differentiated cells that do not express androgen receptor (AR) or prostate-specific antigen (PSA) but instead express neuron-specific proteins, such as aurora kinase A (AURKA), synaptophysin (SYP), and neuron-specific enolase (NSE) [25–27]. These aberrations promote pro-tumorigenic pathways independently from those activated by the AR [28]. Treatment-emergent NEPrCa has similar characteristics but, at variance, it acquires expression of the AR [29]. From a clinical perspective, NEPrCa quickly develops resistance to chemotherapy and is associated with a life expectancy of less than one year [25, 30].

Here we show, for the first time, that αVβ3 integrin expression is increased in NEPrCa, but absent in prostatic adenocarcinomas (ADPrCa). Our immunohistochemical analysis of PrCa samples reveals differential expression of the αVβ3 and αVβ6 integrins. We find that the αVβ3 integrin is highly expressed in metastases from NEPrCa patients while αVβ6 integrin is mostly expressed in ADPrCa lacking neuroendocrine features. We also show that αVβ3 expression is increased in a murine model that lacks the PTEN, RB1, and TRP53 genes and develops NEPrCa resembling its human counterpart. Loss of PTEN and RB1, with intact TRP53, also causes increased expression of αVβ3 integrin, although to a lower extent. Moreover, we report increased αVβ3 integrin expression in the tumors of TRAMP (Transgenic Adenocarcinoma of the Mouse Prostate) mice that develop NEPrCa together with castrate-sensitive ADPrCa. We confirmed these results by screening of 42 LuCaP patient-derived xenografts (PDXs) [31, 32]. Our analysis uncovers a positive correlation between αVβ3 integrin and SYP but not between αVβ6 and this NE marker. Our study provides novel insights into the identification of new
pathways that might promote lineage plasticity among PrCa subtypes for which there is no established therapeutic approach. The differential expression of these two lineage-restricted integrins might also serve as a useful biomarker to predict neuroendocrine differentiation and facilitate patient stratification in PrCa.

**Materials and methods**

**Cell lines**

PrCa C4-2B and LNCaP cell culture conditions have been previously described [10, 33].

**Antibodies**

Immunohistochemistry (IHC) analysis used two different rabbit monoclonal antibodies (Abs) against β3 integrin subunit: one from Cell Signaling (13166S; Figs 1 and 2) and another from AbCam (Ab75872; Fig 4). Moreover, a rabbit polyclonal Ab against SYP (Invitrogen, PA1-1043) and a rabbit polyclonal Ab against chromogranin A (CcA, Invitrogen, 18–0094) were used. For the β6 integrin subunit, a mouse monoclonal Ab against the β6 integrin subunit (6.2A1) [34] was used for immunostaining of human samples, and a human/mouse chimeric Ab against the β6 integrin subunit (ch2A1) [35] was used for SKO, DKO, and TKO murine samples. Immunoblotting analysis used rabbit monoclonal Ab against β3 integrin subunit (Cell Signaling, 13166S), rabbit polyclonal Abs against TSG101 (Abcam, ab30871), actin (Sigma, A2066), and a mouse monoclonal Ab against the β6 integrin subunit (6.2A1).

**Generation of mice carrying prostate-specific TRP53 and RB1 gene deletions**

Mice of genotype PB-Cre4 PTEN<sup>loxP/loxP</sup>, PB-Cre4 PTEN<sup>loxP/loxP</sup> RB1<sup>loxP/loxP</sup>, or PB-Cre4 PTEN<sup>loxP/loxP</sup> RB1<sup>loxP/loxP</sup> TRP53<sup>loxP/loxP</sup> were generated as previously described [36, 37]. Briefly, mice carrying different combinations of the PTEN<sup>loxP</sup>, RB1<sup>loxP</sup>, and TRP53<sup>loxP</sup> alleles were interbred, with the ARR2PB-Cre transgene from the PB-Cre4 line always carried through males. Mice used in this analysis are on a C57BL/6 and 129SVJ mixed genetic backgrounds. Mice were backcrossed to the C57BL/6 strain for at least 5 generations. Genotypes were designated as SKO (single PTEN knock-out), DKO (double PTEN:RB1 knock-out), and TKO (triple PTEN:RB1:TRP53 knock-out). Non-recombinant littermates were used as a control. The mice were euthanized using CO<sub>2</sub> and cervical dislocation when the tumor length was approximately 2 cm. All of these mice were maintained following guidelines of the Institutional Animal Care and Use Committee (IACUC), and were bred and kept at Roswell Park Comprehensive Cancer Center (Buffalo, NY, USA).

**TRAMP (Transgenic Adenocarcinoma of the Mouse Prostate) mice**

Male TRAMP mice were generated as described previously [38]. Twenty-four male TRAMP mice were used. No female mice were analyzed in this study. The mice were euthanized using CO<sub>2</sub> and cervical dislocation when the tumor volume was approximately 10,000 mm<sup>3</sup>. Care of animals was in compliance with standards established by the Office of Laboratory Animal Welfare, NIH, Department of Health and Human Services. All mice were maintained following recommendations of the IACUC. Experimental protocols were approved by IACUC.

**PDX establishment**

The acquisition of PrCa patient tissues and their use to establish PDX models have been described [32]. The vast majority of implanted tissues was from metastatic foci obtained at
tissue acquisition necropsy in a manner which limited warm ischemic time as much as possible (aiming for 4–8 hours after death). A few samples of primary PrCa were obtained from surgical procedures. Harvested tumor tissues were evaluated by pathologists, and viable tumor tissue was macro-dissected to minimize content of stroma, fat, and necrotic tissue. Tumor fragments were implanted subcutaneously in 6- to 8-week-old intact male athymic Nu/Nu (NU-Foxn1nu) or CB-17 severe combined immunodeficient (SCID, CB17/Prkdcscid/IcrCrl) mice (Charles River Laboratory). Tumor samples were harvested from later passages (>3) and frozen or embedded in paraffin for characterization. LuCaP PDXs are maintained by constant passaging in SCID mice. The levels of SYP in the LuCaP PDX were assessed by IHC analysis.

Fig 1. αVβ3 integrin is selectively upregulated in the primary tumors of mice carrying neuroendocrine prostate cancer. Immunostaining of the αVβ3 integrin (top panels), αVβ6 integrin (middle panels), and SYP (bottom panels) in prostate tumors from murine models with genetic knockdown of PTEN (SKO; n = 5), PTEN and RB1 (DKO; n = 5), and PTEN, RB1, and TRP53 (TKO; n = 5) in the prostatic epithelium. The bar at the bottom right corner of each panel represents 50 μm. First column: SKO; second column: DKO; third column: TKO.
The αVβ3 integrin is a marker of neuroendocrine prostate cancer

**GEM:**
(Ptenf/f: Rb1f/f)

αVβ3 Integrin

αVβ6 Integrin

SYP

**DKO**
(Ptenf/f: Rb1f/f: Trp53f/f)

**TKO**

Lung Metastases

n = 5

n = 5
Immunohistochemistry (IHC)

IHC was performed on tissue sections from SKO (n = 5), DKO (n = 5), and TKO (n = 5) prostate tumors and lung metastases, from TRAMP murine primary tumors, and on LuCaP PDX TMA containing 42 PDX models. Of the 24 TRAMP mice analyzed, 13 exhibited a NE phenotype, 11 presented adenocarcinoma lesions, and 5 displayed both characteristics. The tissue sections were baked at 60˚C for 1 hour, followed by deparaffinization with xylene (3 min × 2), and rehydration through a graded ethanol series (100%, 90%, 70%, 50%, 30% for 3 min each) followed by deionized water (3 min × 2). The sections were incubated with 3% H₂O₂ solution for quenching endogenous peroxidase activity, followed by heat-induced antigen retrieval for the β3 integrin subunit, SYP or chromogranin (CgA) that was performed in citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) at 95˚C for 15 min. For β6 integrin subunit immunostaining, antigen retrieval was performed using pepsin (0.5% in 5 mM HCl) digestion for 15 min at 37˚C. Sections were washed once with deionized water for 5 min, followed by a phosphate buffer saline (PBS) wash for 5 min, and blocked with 5% goat serum in PBST (PBS, 0.1% Tween20) for 2 hours. The tissue sections were incubated overnight at 4˚C with Abs against β3 integrin subunit (1:25), β6 integrin subunit (2 μg/ml), CgA (1 μg/ml), SYP (5 μg/ml), or the respective IgG isotype, which was used as negative control. The following day, the tissue sections were washed with PBST (5 min × 2), followed by PBS (5 min), and incubated with secondary Abs (biotinylated goat anti-rabbit IgG in PBST for β3 integrin, SYP, or CgA, and biotinylated goat anti-human or horse anti-mouse IgG for β6 integrin, 10 μg/ml in PBST) for 30 min at room temperature. The unbound secondary Ab was washed with PBST (5 min × 2), followed by PBS (5 min). The tissue sections were incubated with streptavidin horse-radish peroxidase (SAP, 5 μg/ml in PBS) for 30 min at room temperature and the unbound SAP was washed with PBST (5 min × 2), followed by PBS (5 min). The chromogenic reaction product was developed by adding substrate chromogen 3,3′-diaminobenzidine solution (DAB substrate kit). The DAB reaction was stopped by rinsing the tissue sections in deionized water. The sections were counterstained with Harris hematoxylin, dehydrated in a graded ethanol series (30%, 50%, 70%, 90%, 100% for 5 min each) followed by xylene (5 min × 2), dried, and finally mounted with Permount (Vector Laboratories).

LuCaP TMA immunohistochemical assessment and statistical analysis

LuCaP PDX TMA immunostaining was scored by multiplying each staining intensity level (“0” for no stain, “1” for faint stain, and “2” for definitive stain) by the percentage of cells at each staining level. The multiplicands provided a final score for each sample (score range was 0 to 200). The score for each LuCaP core was the average of the scores of each triplicate. Relative detection levels of SYP were provided by Dr. Corey and defined as 0 (-), 1 (+), 2 (++), and 3 (+++). The normalization was performed by assigning to the higher score for each immunostaining (αVβ3, αVβ6, and SYP) a value of 100. Correlation analysis between the integrin scores and the expression levels of SYP and its significance was performed using Spearman correlation (Matlab v.R2016a).

RNA-sequencing (RNA-seq)

RNA-seq was performed as previously reported in [39] and publicly available on GEO Expression Omnibus (accession number: GSE90891). Briefly, RNA-seq was performed on SKO
(n = 4), DKO (n = 5), and TKO (n = 4) prostate tumors and on normal prostate (n = 4) by the Roswell Park Cancer Institute Genomics shared resource. Sequencing libraries were prepared with the TruSeq Stranded Total RNA kit (Illumina Inc) from 1 μg total RNA following manufacturer’s instructions. After ribosomal RNA depletion, RNA was purified, fragmented, and primed for cDNA synthesis. Fragmented RNA was reverse transcribed into first-strand cDNA using random primers. AMPure XP beads were used to separate the cDNA from the second-strand reaction mix resulting in blunt-ended cDNA. A single ‘A’ nucleotide was then added to the 3’ ends of the blunt fragments. Multiple indexing adapters, containing a single ‘T’ nucleotide on the 3’ end of the adapter, were ligated to the ends of the cDNA to prepare them for hybridization onto a flow cell. Libraries were purified and validated for the appropriate size on a 2100 Bioanalyzer High Sensitivity DNA chip (Agilent Technologies, Inc.). The DNA library was quantitated using KAPA Biosystems qPCR kit and normalized to 2 nM prior to pooling. Libraries were pooled in an equimolar fashion and diluted to 10 pM. Library pools were clustered and run on a HiSeq2500 rapid mode sequencer according to the manufacturer’s recommended protocol (Illumina Inc.).

Raw sequencing reads passing the Illumina RTA quality filter were pre-processed using FASTQC for sequencing base quality control. Reads were mapped to the mouse reference genome (mm9) and RefSeq annotation database using Tophat. A second round of quality control using RSeQC was applied to mapped bam files to identify potential RNA-seq library preparation problems. The number of reads aligning to each gene was calculated using HTSeq, and for each gene, the corresponding RPKM value was calculated.

For differential gene expression analysis, RNA-seq counts were processed to remove genes lacking expression in more than 80% of samples. Scale normalization was done using the Limma package in R. After Voom transformation, data from primary SKO, DKO, and TKO tumors were compared to generate differentially expressed gene lists with P < 0.05 and logFC > 1.5.

**Human subject inclusion criteria**

Three metastatic ADPrCa tissue samples (Gleason Score GS 9 [n = 1] and GS 10 [n = 2]) were obtained from the Department of Pathology at Thomas Jefferson University (Philadelphia, PA). Additionally, four human malignant ADPrCa tissue samples (GS 7 [n = 3] and GS 10 [n = 1]) were obtained from the Cooperative Human Tissue Network (CHTN) Western Division at Vanderbilt University Medical Center, TN, or Mid-Atlantic Division at University of Virginia, VA. The CHTN is funded by the National Cancer Institute and other investigators may have received specimens from the same subjects. All specimens were de-identified and discarded in accordance with IRB-approved protocols.

**siRNA transfection and immunoblotting analysis**

Downregulation of AR was accomplished using siRNA SMARTPool (Dharmacon, L-003400-00-0005) and non-targeting siRNA as a control (Dharmacon, D-001810-10-05). Transfection of siRNA and immunoblotting analysis were performed as previously described [21].

**Results**

**The αVβ3 integrin is selectively upregulated in NEPrCa murine models**

In a recent study, we have shown that the αVβ3 integrin is found in small extracellular vesicles released by cancer cells and that small extracellular vesicles containing αVβ3 have a unique ability to promote NED of PrCa in vivo [7]. Based on these findings, we hypothesized that
elevated expression levels of αVβ3 might correlate with NED in PrCa. We tested this hypothesis by analyzing the levels of αVβ3 and αVβ6 integrins in primary tumors, as well as lung metastatic lesions, from NEPrCa mice carrying PTEN, RB1, and TRP53 triple conditional knockouts in the prostatic epithelium (PBCre4 PTENloxP/loxP RB1loxP/loxP TRP53loxP/loxP, TKO). This model has been reported to develop NEPrCa similar to its human counterpart [39]. We compared the TKO model to a double knock-out model lacking PTEN and RB1 in the prostate (PBCre4 PTENloxP/loxP RB1loxP/loxP, DKO). In addition, we analyzed a PTEN single conditional knock-out mouse model (PBCre4 PTENloxP/loxP, SKO) whose gene expression signature has been shown to be comparable to human ADPrCa [39]. The immunostaining analysis reveals high levels of the αVβ3 integrin (Figs 1 and 2, top panels) which correlate with SYP expression (Figs 1 and 2, bottom panels) in the prostate tumors (Fig 1) and lung metastatic lesions (Fig 2) of DKO and TKO mice (n = 5 for each group). The results are consistent in all samples except for one of the DKO samples which does not exhibit detectable αVβ3 integrin expression. In the tumors from the SKO mice, the αVβ3 integrin is not detectable (Fig 1, top panels), whereas the αVβ6 integrin is highly expressed in SKO prostate tumor samples (Fig 1, middle panels), and is low with some patchy positivity in the DKO and TKO primary tumors (Fig 1, middle panels). Consistent with these results, lung metastatic lesions from DKO and TKO mice show some patchy positivity for the αVβ6 integrin (Fig 2, middle panels) but at a considerably lower level than for αVβ3. We did not observe any metastases in SKO mice.

Table 1. RNA sequencing analysis shows increased expression of ITGB3 mRNA in DKO and TKO tumors.

<table>
<thead>
<tr>
<th></th>
<th>WT (n = 4)</th>
<th>SKO (n = 4)</th>
<th>DKO (n = 5)</th>
<th>TKO (n = 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ITGB3</td>
<td>23.8</td>
<td>1145.5</td>
<td>3536.4</td>
<td>3018</td>
</tr>
<tr>
<td>ITGAV</td>
<td>764.3</td>
<td>22121.3</td>
<td>3262.6</td>
<td>4857.3</td>
</tr>
<tr>
<td>ITGB6</td>
<td>22.8</td>
<td>3652.5</td>
<td>2113.8</td>
<td>1035</td>
</tr>
<tr>
<td>PARP1</td>
<td>580.8</td>
<td>4434.3</td>
<td>15946.2</td>
<td>10862.5</td>
</tr>
<tr>
<td>POU3F4</td>
<td>0</td>
<td>86.6</td>
<td>75.5</td>
<td></td>
</tr>
</tbody>
</table>

Normalized read counts for the β3 integrin subunit (ITGB3), αV integrin subunit (ITGAV), β6 integrin subunit (ITGB6), PARP1, and BRN4 (POU3F4) RNA levels in normal prostate (WT), as well as in SKO, DKO, and TKO prostate tumor samples.

https://doi.org/10.1371/journal.pone.0244985.t001
We also performed immunohistochemical analysis of tumor samples from TRAMP mice to assess the levels of αVβ3 and αVβ6 integrin expression in their tumors. This mouse model, which is known to have RB and p53 inactivated, develops NEPrCa together with ADPrCa [43, 44]. Our immunostaining shows that the NE marker chromogranin A (CgA) co-occurs with the αVβ3 integrin in 10 of the 13 TRAMP NE tumor samples analyzed (Fig 3). The αVβ6 integrin, however, is not detected in the NE tumors from the TRAMP model (Fig 3). In contrast, the αVβ6 integrin is detected exclusively in the ADPrCa, NE-negative areas of the TRAMP tumor samples (Fig 3). Our results, from the DKO and TKO NE mouse genetic models as well as the TRAMP mice, taken together, clearly demonstrate a consistent correlation between the high expression of αVβ3 integrin and NEPrCa occurrence. Conversely, ADPrCa tumors are consistently associated with expression of the alternative αVβ6 integrin subtype.

Expression of αVβ3 integrin and synaptophysin correlates in patient-derived xenografts

To confirm these results in human specimens, we conducted an immunohistochemical analysis of 42 LuCaP PDXs [31, 32]. These PDX models were generated by implanting primary PrCa or metastatic lesion tumor fragments from PrCa patients into immunocompromised mice [32], and the resulting PDX models were subsequently characterized for their expression of NE markers [31]. We assessed the presence of αVβ3 or αVβ6 integrin using immunohistochemical analysis and scored the immunostaining intensity of each LuCaP core in the tumor micro-array (TMA) using the scoring system described in the Materials and Methods section. We observe a positive correlation between the αVβ3 integrin and the NE marker SYP (Fig 4A and 4B, r = 0.42; P = 0.0046). In contrast, the αVβ6 integrin shows no correlation with SYP (Fig 4A and 4B, r = 0.22; P = 0.1622), confirming the results described above obtained for mouse tumor samples.

We further validated the results obtained using the LuCaP PDX TMA by screening PrCa samples from the Department of Pathology at Thomas Jefferson University and the Cooperative Human Tissue Network. Of the 7 ADPrCa primary tumors none expresses αVβ3 (Fig 4C). On the other hand, as previously reported [21], most of the ADPrCa express αVβ6 which was used as positive control. These findings suggest a differential expression of these two αV integrins during PrCa progression, whereby the αVβ3 integrin is specifically expressed in NEPrCa samples, and in contrast, the αVβ6 integrin is specifically expressed in ADPrCa samples lacking NE characteristics.

Loss of androgen receptor signaling does not result in upregulation of αVβ3 or αVβ6 integrin expression in PrCa cell lines

NEPrCa is characterized by the activation of pro-tumorigenic pathways independently from the AR signaling [28]. We hypothesized that loss of AR signaling might induce upregulation of the αVβ3 integrin in LNCaP and C4-2B, two AR positive PrCa cell lines. To test our hypothesis, we downregulated AR expression in LNCaP and C4-2B cells using siRNA. Our results show that downregulation of AR in C4-2B or LNCaP cells does not upregulate αVβ3 (Fig 5A) or αVβ6 integrin (Fig 5B) expression. Thus, it is possible that other factors in the tumor microenvironment contribute to the regulation of αVβ3 integrin and αVβ6 integrin expression after AR signaling loss.

Discussion

Our results demonstrate that increased expression of the αVβ3 integrin correlates with the occurrence of NE markers in human patients’ samples and murine models. In contrast, the
Fig 3. Selective upregulation of αVβ3 integrin in the TRAMP (Transgenic Adenocarcinoma of the Mouse Prostate) mice. IHC staining of αVβ3 (first row), αVβ6 (second row), and chromogranin A (CgA, third row) of prostate tumors from TRAMP mice (n = 24). Of the 24 samples analyzed, 13 show only a NE phenotype, 11 show only ADPrCa lesions, and 5 show both characteristics. IgG was used as negative control (last row). The bar at the bottom right corner of each panel represents 50 μm. Left column, ADPrCa; right column, NEPrCa.

https://doi.org/10.1371/journal.pone.0244985.g003
**Fig 4.** Increased expression of the αVβ3 integrin, but not αVβ6, correlates with the neuroendocrine marker SYP in LuCaP PDXs and human prostate tumor samples. Immunohistochemical analysis of 42 LuCaP PDX models. (A) Representative IHC staining for αVβ3 (left) or αVβ6 (right) integrin of SYP positive (top row) or SYP-negative (bottom row) LuCaP PDX models is shown. The bar at the bottom right corner of each panel represents 20 μm. (B) Heat map of the signature score for SYP, αVβ3 or αVβ6 integrin of each LuCaP is shown. Raw data are reported in the S1 Table. (C) Immunostaining analysis of αVβ3 and αVβ6 integrins and SYP primary tumors from ADPrCa patients. The bar at the bottom right corner of each panel represents 20 μm.

**https://doi.org/10.1371/journal.pone.0244985.g004**
αVβ6 integrin is expressed in human and murine ADPrCa, suggesting that the αVβ3, but not αVβ6, integrin might serve as a suitable biomarker to characterize NED in the context of PrCa.

Here, we show that these two integrins are differentially expressed in ADPrCa and NE cancers. Specifically, expression of the αVβ3 integrin in primary prostate tumors and metastatic lesions of mice carrying deletions of the PTEN (SKO), RB1 and PTEN (DKO) or RB1, PTEN, and TP53 (TKO) inversely correlates with αVβ6. Expression of the αVβ3 integrin in primary prostate tumors of mice carrying deletions of the PTEN (SKO) is undetectable, while it is significantly increased in DKO or TKO tumors and metastatic lesions. This indicates that RB1 loss, and consequent activation of transcription factors of the E2F family [45–47], is sufficient to induce αVβ3 expression in these models. This integrin expression persists in TKO tumors which, in contrast to DKO tumors exhibiting both SYP and AR expression, develop homogenous AR-negative NEPrCa, similar to its human counterpart [39]. It remains to be investigated whether downregulation of αVβ6 and gain of the αVβ3 integrin occur in CRPrCa since RB1 is known to influence integrin expression [48, 49], and its loss occurs frequently in human CRPrCa [50, 51].

A factor that may influence the processing of the αVβ3 integrin, is the expression of the αV subunit which is required for the heterodimeric complex. The RNA analysis summarized here (Table 1) indicates that the levels of the αV integrin subunit (ITGAV) become limiting and that β3 acts in a dominant fashion over the β6 integrin subunit.

Fig 5. Downregulation of androgen receptor does not increase αVβ3 or αVβ6 integrin expression. Immunoblotting analysis of C4-2B and LNCaP cell lysates after AR downregulation by siRNA to AR. (A) Expression levels of αVβ3 integrin in C4-2B and LNCaP cells after AR downregulation. Immunoblotting was performed under reducing conditions. (B) Expression levels of αVβ6 integrin in C4-2B and LNCaP cells after AR downregulation. Immunoblotting was performed under non-reducing conditions. Actin or TSG101 serves as loading controls. NS, non-silencing.

https://doi.org/10.1371/journal.pone.0244985.g005
We also detect high αVβ3 integrin expression in the NE areas of primary tumors from TRAMP mice that develop NEPrCa together with ADPrCa. In contrast, we detect the related αVβ6 integrin in the ADPrCa areas of the TRAMP tumors. Our findings underline the specificity of the αVβ3 integrin in NEPrCa, nominating this integrin as a potential biomarker for patient stratification in PrCa treatment. Our future studies will benefit from the use of mice carrying deletion of the αVβ3 integrin crossed with the DKO, TKO, or TRAMP mice, in order to shed new light on the mechanism of action of the αVβ3 integrin in NEPrCa development and/or metastatic progression.

Multiple strategies have been developed to target the αVβ3 integrin due to its role in tumor angiogenesis and tumor growth [16]. For example, LM609, an inhibitory antibody against the αVβ3 integrin, reduced angiogenesis and tumor growth in a SCID mouse/human chimeric model for breast cancer [52]. Its humanized counterpart JC-7U IgG1 has been reported to inhibit tumor growth in a Kaposi sarcoma mouse model and was also able to inhibit, in part, the binding of human immunodeficiency virus (HIV-1) Tat protein to αVβ3 integrin, which is necessary to stimulate Kaposi sarcoma growth [16, 53]. Previous studies also reported the ability of the αVβ3 integrin to support metastasis in PrCa [54] as well as other cancers [55–58]. Likewise, the expression of the αVβ3 integrin conceivably facilitates the metastatic behavior of NEPrCa. In support of this idea, our SKO mouse model (PB-Cre4 PTENloxP/loxP) does not metastasize and expresses low levels of αVβ3 integrin, whereas DKO and TKO, the two NE models that acquire αVβ3 integrin expression as a consequence of additional RB1 knock-out, develop metastases in the lungs [39]. We can speculate that upon RB1 loss, downregulation of αVβ6 and gain of the αVβ3 integrin are required in the primary tumors in the early stages of NED to confer upon NEPrCa the ability to metastasize in different sites (Fig 6). Upon metastasizing, the αVβ3 integrin expression is sustained as shown here and as previously described [7] in NEPrCa bone metastasis, indicating additional pro-survival functions provided by this integrin.

Whether one or more of the many pathways activated by the αVβ3 integrin is involved in NED remains to be established. For example, the expression of the αVβ3 integrin reportedly stimulates cell migration by activation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway [59]. Other studies have demonstrated that AKT1 is involved in stabilizing N-MYC [60, 61], one of the main promoters of NED in PrCa [62]. Since pAKT is not detectable in TKO prostate tissue [39], we speculate that pAKT activated by αVβ3 primes the cells to stabilize N-MYC but is not required for long-lasting NED. The RNA-seq analysis presented here highlights potential downstream effectors of αVβ3. For example, αVβ3 integrin might be able to induce NED in PrCa by upregulating Trop2 expression, which is known to induce NEPrCa by upregulation of PARP1 [40]. Underlining the importance of targeting this pathway to prevent or delay the most aggressive forms of PrCa, the U.S. Food and Drug Administration has recently approved olaparib, a PARP1 inhibitor [63], for the treatment of metastatic CRPrCa. However, there are as yet no reports on the safety or efficacy of olaparib for the treatment of NEPrCa.

Our previous study demonstrates that the dysregulated expression of the αVβ3 integrin in small extracellular vesicles released by PrCa cells promotes a shift in lineage plasticity towards a NE lineage [7]. Moreover, although our group has reported that the αVβ6 integrin, in small extracellular vesicles released by cancer cells, induces M2 polarization in recipient monocytes [64] and stimulates angiogenesis in endothelial cells during cancer progression [65], is absent in NEPrCa. Here we show that the αVβ3 integrin is upregulated in tumor samples from patients affected by NEPrCa and in corresponding NE murine models. Moreover, our findings demonstrate that conversely, the expression of the αVβ6 integrin is upregulated in ADPrCa samples from humans and mice. It is therefore reasonable to speculate that monitoring the expression of these two integrins during PrCa progression will help to predict the potential for NED in PrCa patients. Moreover, based on our emerging findings that NE metastatic lesions express relatively
high levels of the αVβ3 integrin, targeted therapies directed against this integrin might prove to be effective in preventing or delaying plasticity and metastasis in NEPrCa [56].

Supporting information
S1 Table. Raw data of the signature score used to generate the heatmap in Fig 4. (TIF)
S1 Raw images. (PDF)

Acknowledgments
The authors would like to thank Dr. Misha Beltran and Dr. Martin Backht for useful discussions about NEPrCa and sharing with us their expertise in NED; Dr. Dario C. Altieri and Dr.
Shelia Violette, for the insightful discussion; Dr. Huimin Lu for immunostaining assistance; Dr. Mark Fortini and Jennifer Wilson for editing comments; and Veronica Robles for administrative assistance with the preparation of the manuscript. We would also like to thank Wei Jiang and Zhijiu Zhong, Translational Research/Pathology Facility at Thomas Jefferson University for technical support with tissue processing. Moreover, we would like to thank Dr. Colm M. Morrisey for useful discussion.

Author Contributions
Conceptualization: Fabio Quaglia, Lucia R. Languino.
Data curation: Fabio Quaglia, Yanqing Wang, Amy C. Mandigo.
Funding acquisition: David W. Goodrich, Karen E. Knudsen, Lucia R. Languino.
Investigation: Fabio Quaglia, Shiv Ram Krishn, Yanqing Wang.
Methodology: Fabio Quaglia.
Resources: Yanqing Wang, David W. Goodrich, Paul H. Weinreb, Eva Corey, Lucia R. Languino.
Supervision: William K. Kelly.
Validation: Peter McCue, Andrew V. Kossenkov.
Writing – original draft: Fabio Quaglia, Lucia R. Languino.
Writing – review & editing: David W. Goodrich, Andrew V. Kossenkov, Amy C. Mandigo, Karen E. Knudsen.

References
The αvβ3 integrin is a marker of neuroendocrine prostate cancer


